跳到主要內容區塊
卷期標題作者頁數
Volume 27(2019) > Number 4Simultaneous determination of cardiovascular drugs in dried blood spot by liquid chromatography-tandem mass spectrometryHyung Min Kim, Ju-Hwan Park, Nguyen Phuoc Long, Dae-Duk Kim, Sung Won Kwon906-914
Volume 27(2019) > Number 410 Estimation of nizatidine gastric nitrosatability and product toxicity via an integrated approach combining HILIC, in silico toxicology, and molecular dockingRania El-Shaheny, Mohamed Radwan, Koji Yamada, Mahmoud El-Maghrabey915-925
Volume 27(2019) > Number 4ACKNOWLEDGMENT OF REVIEWERSnone926-927
Volume 27(2019) > Number 3Next generation probiotics in disease ameliorationChih-Jung Chang, Tzu-Lung Lin, Yu-Ling Tsai, Tsung-Ru Wu, Wei-Fan Lai, Chia-Chen Lu, Hsin-Chih Lai615-622
Volume 27(2019) > Number 3Revisit gut microbiota and its impact on human health and diseaseRui-xue Ding, Wei-Rui Goh, Ri-na Wu, Xi-qing Yue, Xue Luo, Wei Wei Thwe Khine, Jun-rui Wu, Yuan-Kun Lee623-631
Volume 27(2019) > Number 3Psychobiotics in mental health, neurodegenerative and neurodevelopmental disordersLi-Hao Cheng, Yen-Wenn Liu, Chien-Chen Wu, Sabrina Wang, Ying-Chieh Tsai632-648
Volume 27(2019) > Number 3Potential prebiotics and their transmission mechanisms: Recent approachesIshu Khangwal, Pratyoosh Shukla649-656
Volume 27(2019) > Number 3Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary diseaseMeng-Ting Wang, Jyun-Heng Lai, Chen-Liang Tsai, Jun-Ting Liou657-670
Volume 27(2019) > Number 3The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyondLin-Chau Chang671-678
Volume 27(2019) > Number 3Direct injection high performance liquid chromatography coupled to data independent acquisition mass spectrometry for the screening of antibiotics in honeyAnnie von Eyken, Daniel Furlong, Samareh Arooni, Fred Butterworth, Jean-François Roy, Jerry Zweigenbaum, Stéphane Bayen679-691
2213筆資料, 第31/ 222
最前頁上一頁下一頁最末頁